2nd Peptide Formulation & Delivery Innovation Summit
Buoyed by advancements in formulation technologies such as permeation enhancers, nanoparticle encapsulation and structural modification abilities, oral delivery and bioavailability of peptide-based therapeutics has become a clinical reality that increasing numbers of drug developers are pursuing. However, several challenges still remain within the industry.
As such, the 2nd Peptide Formulation & Delivery Innovation Summit (June 24 - 26, 2025 | Boston, MA) returns as the only industry-specific event helping you catapult peptide-based drugs through formulation and delivery gridlocks, towards commercialization and patients in need.
With 18 industry expert speakers from pharma and biotech, here’s a sneak peek of the must-attend sessions we have created just for you:
- Predict the translatability of discovery and preclinical systems into humans to accelerate peptides into the clinic with Eli Lilly
- Explore innovative technologies and advanced formulations for oral delivery to achieve double-digit peptide bioavailability with AltrixBio, Divincell, and Aviceda Therapeutics
- Discuss the considerations for high-concentration SC or multi-dose peptide injectables as well as analytical development challenges with Novo Nordisk and University of Miami
- Push the limits of peptide formulation through inhaled and intradermal to maximize pan-disease applications with Neurelis and Carocell Bio
- Learn about peptide formulation and delivery consideration from cutting-edge biotechs in the clinic with Xeris Pharmaceuticals and Neuraly
See our unrivalled speaker faculty and list of topics to be discussed covering oral, inhaled, intradermal and parenteral delivery systems in your exclusive official program here.
We hope you can join us in this industry-focused conference designed to help you optimize peptide-based drug formulation without compromising efficacy, expand into pan-disease settings with diverse delivery systems, and enhance patient adherence as peptides take market share from more established drug modalities.
